IN8BIO, INC. Deferred Income Tax Expense (Benefit)
IN8BIO, INC. (INAB) reported Deferred Income Tax Expense (Benefit) of -$2.42 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-12
- IN8BIO, INC. deferred income tax expense (benefit) for fiscal 2025 was -$2.42M.
- IN8BIO, INC. deferred income tax expense (benefit) for fiscal 2024 was -$5.55M.
- IN8BIO, INC. deferred income tax expense (benefit) for fiscal 2023 was -$5.74M.
- IN8BIO, INC. deferred income tax expense (benefit) for fiscal 2022 was -$4.51M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$2.42M 10-K · filed 2026-03-12 |
| 2024-12-31 | -$5.55M 10-K · filed 2026-03-12 |
| 2023-12-31 | -$5.74M 10-K · filed 2025-03-13 |
| 2022-12-31 | -$4.51M 10-K · filed 2024-03-14 |
| 2021-12-31 | -$4.61M 10-K · filed 2023-03-30 |
| 2020-12-31 | -$2.69M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |